1. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. (15th October 2014) Authors: Élez, E.; Kocáková, I.; Höhler, T.; Martens, U. M.; Bokemeyer, C.; Van Cutsem, E.; Melichar, B.; Smakal, M.; Csőszi, T.; Topuzov, E.; Orlova, R.; Tjulandin, S.; Rivera, F.; Straub, J.; Bruns, R.; Quaratino, S.; Tabernero, J. Journal: Annals of oncology Issue: Volume 26:Number 1(2015:Jan.) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗